Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review
AR Kreimer, GM Clifford, P Boyle, S Franceschi - … Epidemiology Biomarkers & …, 2005 - AACR
Mucosal human papillomaviruses (HPV) are the cause of cervical cancer and likely a subset
of head and neck squamous cell carcinomas (HNSCC), yet the global prevalence and type …
of head and neck squamous cell carcinomas (HNSCC), yet the global prevalence and type …
Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer
GM Clifford, RK Rana, S Franceschi, JS Smith… - … Biomarkers & Prevention, 2005 - AACR
Low-grade squamous intraepithelial lesions (LSIL) associated with certain human
papillomavirus (HPV) genotypes may preferentially progress to cervical cancer. HPV …
papillomavirus (HPV) genotypes may preferentially progress to cervical cancer. HPV …
Prevalence of oral HPV infection in the United States, 2009-2010
ML Gillison, T Broutian, RKL Pickard, Z Tong, W Xiao… - Jama, 2012 - jamanetwork.com
Context Human papillomavirus (HPV) infection is the principal cause of a distinct form of
oropharyngeal squamous cell carcinoma that is increasing in incidence among men in the …
oropharyngeal squamous cell carcinoma that is increasing in incidence among men in the …
Improved survival of patients with human papillomavirus–positive head and neck squamous cell carcinoma in a prospective clinical trial
Background The improved prognosis for patients with human papillomavirus (HPV)–positive
head and neck squamous cell carcinoma (HNSCC) relative to HPV-negative HNSCC …
head and neck squamous cell carcinoma (HNSCC) relative to HPV-negative HNSCC …
Distinct risk factor profiles for human papillomavirus type 16–positive and human papillomavirus type 16–negative head and neck cancers
Background High-risk types of human papillomavirus (HPV), including HPV-16, cause a
subgroup of head and neck squamous cell carcinomas (HNSCCs). We examined whether …
subgroup of head and neck squamous cell carcinomas (HNSCCs). We examined whether …
Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
SN Tabrizi, JML Brotherton, JM Kaldor… - The Lancet infectious …, 2014 - thelancet.com
Background After the introduction of a quadrivalent human papillomavirus (HPV) vaccination
programme in Australia in April, 2007, we measured the prevalence of vaccine-targeted and …
programme in Australia in April, 2007, we measured the prevalence of vaccine-targeted and …
[HTML][HTML] Prevalence of HPV infection among females in the United States
EF Dunne, ER Unger, M Sternberg, G McQuillan… - Jama, 2007 - jamanetwork.com
Context Human papillomavirus (HPV) infection is estimated to be the most common sexually
transmitted infection. Baseline population prevalence data for HPV infection in the United …
transmitted infection. Baseline population prevalence data for HPV infection in the United …
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study
Summary Background Human papillomaviruses (HPVs) cause genital warts and cancers in
men. The natural history of HPV infection in men is largely unknown, and that information is …
men. The natural history of HPV infection in men is largely unknown, and that information is …
Male circumcision for the prevention of HSV-2 and HPV infections and syphilis
AAR Tobian, D Serwadda, TC Quinn… - … England Journal of …, 2009 - Mass Medical Soc
Background Male circumcision significantly reduced the incidence of human
immunodeficiency virus (HIV) infection among men in three clinical trials. We assessed the …
immunodeficiency virus (HIV) infection among men in three clinical trials. We assessed the …
Very low prevalence of vaccine human papillomavirus types among 18-to 35-year old Australian women 9 years following implementation of vaccination
DA Machalek, SM Garland… - The Journal of …, 2018 - academic.oup.com
Introduction A quadrivalent human papillomavirus vaccination program targeting females
aged 12–13 years commenced in Australia in 2007, with catch-up vaccination of 14–26 year …
aged 12–13 years commenced in Australia in 2007, with catch-up vaccination of 14–26 year …